Abivax SA (AAVXF)
OTC
Real-time Data
01:30 PM
Day's Range
139.0052 wk Range
71.25Overview - AAVXF - Abivax SA
Key Statistics
Valuation
Enterprise Value
12.36B
P/E (Trailing)
‪-28.77‬
PEG Ratio
‪1.08‬
Price / Sales (TTM)
‪2,465.09‬
Price / Book
‪22.17‬
EV / EBITDA
‪-41.59‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-4,183.70%‬
Return on Assets
‪-44.65%‬
Return on Equity
‪-157.06%‬
Ownership
Shares Outstanding
79.29M
Float
69.35M
Held by Insiders
‪4.84%‬
Held by Institutions
‪50.10%‬
Price stats
Beta
‪-0.22‬
50-Day Avg
‪120.41‬
200-Day Avg
‪117.74‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AAVXF - Abivax SA
Peers - AAVXF - Abivax SA
Peer Comparison
Compared with companies in Biotechnology listed on OTC.
Profile Summary - AAVXF - Abivax SA
About
Abivax SA is a France-based clinical-stage biotechnology company dedicated to developing innovative therapeutics that modulate the immune response in patients with chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms, particularly through enhanced expression of microRNA-124. Its lead…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
